Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on NRX Pharmaceuticals and raised the price target from $43 to $44, indicating a positive outlook for the company's stock.
September 12, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital has reaffirmed its Buy rating on NRX Pharmaceuticals and increased the price target from $43 to $44, suggesting confidence in the company's future performance.
The increase in the price target from $43 to $44 by Ascendiant Capital, along with the maintained Buy rating, indicates a positive sentiment from the analyst. This is likely to boost investor confidence and could lead to a short-term increase in NRXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100